On Thursday, shares of Hims & Hers Health Inc. (HIMS) surged nearly 14% in pre-market trading, reaching $27.77. The catalyst for the move was the company's announcement that it has begun offering a generic version of the newly launched weight-loss drug Wegovy at a promotional price of $49 per month, which is approximately $100 cheaper than the branded medication. Hims stated that the treatment can be customized for patients who wish to avoid side effects or prefer a pill form over an injection. "We are excited to find ways to continue launching branded treatment options across specialties through our platform. Having more choices available on the platform is the best outcome for our customers," said Andrew Dudum, CEO of Hims, in a statement.